Cullinan Therapeutics, Inc.

CGEM · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
90
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. We pursue promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, we are advancing our mission to deliver new standards ...

Next Earnings

Q2 FY2026 — expected 2026-09-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCGEMdiscussed_in_filing Cybersecurity
topic_mentionCGEMdiscussed_in_filing Cybersecurity
topic_mentionCGEMdiscussed_in_filing Healthcare & Bio
topic_mentionCGEMdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-102025-12-310001193125-26-099362EDGAR95K words
2025-02-272024-12-310000950170-25-028346EDGAR—
2024-03-142023-12-310000950170-24-031143EDGAR—
2023-03-092022-12-310000950170-23-006839EDGAR—
2022-03-172021-12-310000950170-22-004002EDGAR—
2021-03-302020-12-310001564590-21-016312EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-268066EDGAR20K words
2025-08-072025-06-300000950170-25-104551EDGAR—
2025-05-082025-03-310000950170-25-066384EDGAR—
2024-11-072024-09-300000950170-24-122795EDGAR—
2024-08-082024-06-300000950170-24-093320EDGAR—
2024-05-152024-03-310000950170-24-060535EDGAR—
2023-11-082023-09-300000950170-23-060679EDGAR—
2023-08-102023-06-300000950170-23-040964EDGAR—
2023-05-112023-03-310000950170-23-021253EDGAR—
2022-11-142022-09-300000950170-22-024683EDGAR—
2022-08-102022-06-300000950170-22-016258EDGAR—
2022-05-162022-03-310000950170-22-009937EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-100001193125-26-099355EDGAR2K words
2026-01-080001193125-26-006998EDGAR—
2025-12-080001193125-25-310764EDGAR—
2025-11-210001193125-25-291448EDGAR—
2025-11-060001193125-25-268041EDGAR—
2025-11-030001193125-25-261799EDGAR—
2025-09-040000950170-25-112949EDGAR—
2025-08-070000950170-25-104547EDGAR—
2025-06-120000950170-25-085425EDGAR—
2025-06-040000950170-25-081601EDGAR—

90 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001789972
TickerCGEM
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 4a954b1fca7d8a49a27721718f2c41a4d959ed0630e75b5c6df51b2bba43eae4
parent: abaa40080f6b8387ed52c4cfd7d21fccf0b85507c267b8ccf953f314de62c1e6
content hash: ec53d24ec293328daa8d4e3d3e985476f64ffe79a61e11c1c91c99d3a5e71295
signed: 2026-04-13T04:44:17.682Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf